The study team analyzed weight outcomes among GLP-1–naive adults treated with semaglutide, comparing those who received individualized carbohydrate-reduced nutritional therapy plus medication (VINT+IOM) with participants receiving IOM only. The cohort was substantial; investigators report 4,269 total participants across both pathways, and the primary subgroup comprised GLP-1–naive semaglutide users who did not switch medications during follow-up. Using longitudinal linear mixed-effects models adjusted for baseline demographic and clinical factors, the authors observed greater adjusted 12-month weight loss in the VINT+IOM arm versus IOM only—30.7 lb compared with 24.1 lb (P=0.01). Observed percent weight reductions paralleled the adjusted estimates: 13.3% for VINT+IOM versus 11.1% for IOM only. These modeled differences persisted after covariate adjustment, according to the authors, and weight loss trajectories continued from month 6 to month 12 in both care pathways.
The investigators separated outcomes for participants receiving tirzepatide and reported larger absolute and percent changes than for semaglutide users. Adjusted 12-month weight loss with VINT+IOM reached 45.9 lb versus 34.4 lb with IOM only (P=0.003). Observed percent reductions were 19.7% and 15.6%, respectively. The study team noted that responder rates—patients meeting prespecified weight-loss thresholds—favored the VINT+IOM pathway consistently in this subgroup as well. The source did not provide trial-level mechanistic data or details on dietary prescription fidelity beyond describing the nutrition approach as individualized and carbohydrate-reduced.
Investigators expanded the analysis to the full cohort, which included GLP-1–naive participants, individuals with prior GLP-1 exposure, and participants with varying medication trajectories. In that pooled analysis, adjusted 12-month weight loss was 29.4 lb for the VINT+IOM group versus 21.5 lb for IOM only (P<0.001). Observed percent reductions for the overall cohort were 12.7% and 9.6%, respectively. The authors reported that greater weight loss with the combined nutritional-plus-medication pathway was also observable among participants with prior GLP-1 exposure, although the manuscript does not provide subgroup sample sizes in-line in the abstract. The analysis controlled for baseline covariates using mixed-effects models; the source did not report additional sensitivity analyses beyond those summarized in the abstract.
Medication utilization was high across pathways. The authors stated that approximately 80% of participants in both care models achieved a proportion of days covered of at least 80%. Responder analyses—classifying participants by clinically meaningful weight-loss thresholds—favored the VINT+IOM pathway across semaglutide and tirzepatide subgroups, according to the reported results. The manuscript indicates that both pathways included clinician-guided medication management and behavioral coaching as program components, but it did not include more granular adherence metrics, adverse event rates, or per-protocol definitions in the abstract.
This was a retrospective, real-world observational study using de-identified clinical data from a telemedicine obesity program. The authors stated the data were de-identified in accordance with HIPAA and that the study was exempt from formal ethical approval because it constituted secondary analysis of de-identified records. The manuscript is a preprint and has not undergone peer review. Investigators disclosed financial interests: several authors are employees of Virta Health and hold company stock or options. The source noted that all data produced in the study are available on reasonable request to the authors and referenced supplementary material and external links for data/code. The abstract and article text do not detail certain elements that clinicians and researchers may seek before changing practice—specifically, the preprint does not report granular subgroup sample sizes in the abstract, per-participant adverse event rates, or stepwise nutritional protocol adherence metrics. These points remain unanswered in the source and represent limits to interpretation pending peer review and access to full methods and supplementary data.